

Evaluation of an algorithm for intensive subcutaneous insulin therapy in emergency room patients with hyperglycaemia

Submission date 17/07/2006	Recruitment status No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 17/08/2006	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 16/04/2019	Condition category Nutritional, Metabolic, Endocrine	<input type="checkbox"/> Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Prof Ulrich Keller

Contact details
Petersgraben 4
Basel
Switzerland
4031
+41 (0)612 655 078
ukeller@uhbs.ch

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number
NCT00353431

Secondary identifying numbers
EKBB13/06

Study information

Scientific Title

Evaluation of an algorithm for intensive subcutaneous insulin therapy in emergency room patients with hyperglycaemia

Acronym

Euglycemia

Study objectives

Time in the glycaemic target range (5.5 to 7.0 mmol/l) during the period of observation of 48 hours expected to be longer in the intensive insulin group.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Local Ethics Committee of Basel, Switzerland (EKBB) approval, 20/03/2006, ref: 13/06

Study design

Interventional randomised open-label active-controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied

All medical patients with a plasma glucose concentration more than 8 mmol/l

Interventions

Comparison of a normal sliding scale with subcutaneous (s.c.) insulin injections versus the new algorithm with s.c. insulin injections (in both groups NovoRapid ®)

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Subcutaneous insulin

Primary outcome measure

Time in the glycaemic target range (5.5 to 7.0 mmol/l) during the period of observation of 48 hours (expected to be longer in the intensive insulin group).

Secondary outcome measures

1. Time to reach the target range (expected to be shorter in the intensive insulin group)
2. Frequency of hypoglycaemia (plasma glucose less than 3.8 mmol/l) (safety endpoint, expected to be similar in the two groups)
3. Frequency of severe hypoglycaemia (plasma glucose less than 2.5 mmol/l) (safety endpoint, expected to be similar in the two groups)
4. Frequency of hypokalaemia (safety endpoint, expected to be similar in the two groups)

Overall study start date

31/08/2006

Completion date

30/04/2008

Eligibility

Key inclusion criteria

1. All patients with hyperglycaemia (more than 8.0 mmol/l) admitted to the medical emergency room
2. Patients with presumed hospitalisation in the Emergency Room (ER) or medical ward of more than 48 hours duration

Participant type(s)

Patient

Age group

Not Specified

Sex

Both

Target number of participants

140

Total final enrolment

130

Key exclusion criteria

1. Patients in shock (defined as hypotension or shock index more than one with oliguria, changed mental status and metabolic acidosis)

2. Patients with a terminal illness on palliative care
3. Patients with type one diabetes
4. Patients with insulin pump therapy
5. Patients with need for hospitalisation in the intensive or coronary care unit
6. Patients with presumed hospitalisation shorter than 48 hours
7. Known pregnancy (in women of birthbearing age pregnancy test for exclusion mandatory)
8. No informed consent

Date of first enrolment

31/08/2006

Date of final enrolment

30/04/2008

Locations

Countries of recruitment

Switzerland

Study participating centre

Petersgraben 4

Basel

Switzerland

4031

Sponsor information

Organisation

University Hospital of Basel (Switzerland)

Sponsor details

Petersgraben 4

Basel

Switzerland

4031

+41 (0)612 655 078

ukeller@uhbs.ch

Sponsor type

University/education

Website

<http://www.endo-diabasel.ch>

ROR

Funder(s)

Funder type

Industry

Funder Name

Novo Nordisk (Switzerland)

Alternative Name(s)

Novo Nordisk Global

Funding Body Type

Private sector organisation

Funding Body Subtype

For-profit companies (industry)

Location

Denmark

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Basic results				No	No
Results article	results	14/06/2013	16/04/2019	Yes	No